The GioTag Study

A real-world assessment of sequential afatinib and osimertinib for the treatment of patients with EGFR M+ NSCLC whose tumors developed T790M resistance following 1st-line therapy.

Find out more

Indication

GIOTRIF® (afatinib) is an irreversible ErbB inhibitor approved in non-small-cell lung cancer. Find out how your patients could benefit.

Giotrif-afatinib indication lung
Indication Read more

Dosing

GIOTRIF® (afatinib) dose modification can be an important strategy to help manage adverse reactions.

Giotrif-afatinib Dosing
Dosing Read more

AE management

Common AEs associated with GIOTRIF® (afatinib) are generally well managed with supportive care.

Giotrif-afatinib AE management
AE management Read more
Giotrif-afatinib clinical trial

Clinical trial data

Learn more about the LUX-Lung clinical trial programme and explore the clinical trial data for afatinib.

Giotrif-afatinib real world evidence

Real-world evidence

Read the real-world evidence for GIOTRIF® (afatinib) use, demonstrating effectiveness in clinical practice.

Back to top

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie policy
I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information about afatinib for non-small-cell lung cancer treatment.

Country-specific product information

Country-specific product information

Click here for country-specific product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.